-63%

est. 2Y upside i

Series D+

Blood testing device for early diagnosis of cancer and treatment…

Rank

#3783

Sector

Diagnostic Equipment

Est. Liquidity

~5Y

Data Quality

Data: Medium

Delee presents a risky equity opportunity with a low expected upside of 15.5% over a two-year horizon, primarily due to significant regulatory hurdles, high capital intensity, and strong incumbent competition.

Last updated: March 10, 2026

Bull (10%)+100%

Delee successfully completes clinical trials, secures FDA clearance for its CytoCatch™ System, and achieves strong commercial adoption, particularly in new cancer indications. Strategic partnerships with pharmaceutical companies for companion diagnostics drive significant revenue growth to over $50M by 2028, justifying a $150M+ valuation (3x current assumed valuation) as a leader in specialized CTC isolation.

Base (45%)+50%

Delee progresses with clinical studies and gains initial FDA clearance for research use, expanding its customer base among research centers. Commercialization for diagnostic use faces moderate challenges and slower adoption due to established competitors like CellSearch. Revenue grows steadily to $15-20M by 2028, leading to a modest valuation increase to $75M (1.5x current assumed valuation).

Bear (45%)-60%

Delee encounters significant delays or setbacks in clinical trials or FDA clearance, leading to increased capital requirements and further dilution. Incumbent competitors with broader platforms or more advanced regulatory status capture market share, limiting Delee's commercial traction. The company struggles to raise subsequent funding rounds, resulting in a down round or acquisition at a significantly reduced valuation of $20M or less, wiping out most common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Based on an assumed $50M valuation, investors hold $4M in liquidation preferences (8% of valuation) ahead of common stock.

Dilution Risk

high

Significant future dilution is highly likely as the company will need substantial capital for ongoing clinical trials, FDA approval, and commercialization efforts.

Secondary Liquidity

none

No active secondary market or tender offers are expected for a company at this early stage of commercialization and funding.

Questions to Ask at the Interview

Strategic questions based on Delee's data — designed to show you've done your homework.

  • 1

    “Given CellSearch's FDA approval and established presence, how does Delee plan to differentiate its CytoCatch™ System beyond the technical advantages of isolating heterogeneous cells, particularly in terms of clinical adoption, reimbursement, and market penetration strategies?”

  • 2

    “With $5M in revenue and $4M in total funding, what is the company's current burn rate and runway, and what are the key milestones and capital requirements anticipated for achieving FDA clearance and scaling commercialization?”

  • 3

    “Considering the 'Later Stage VC' round in 2023, what is the company's current valuation, and what is the expected timeline and strategy for a liquidity event for employees, such as an IPO or acquisition, especially given the capital-intensive nature of medical device development?”

Community

Valuation Sentiment

Our model estimates -63% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.